Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 24

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 24
---
 level, there is little recognition
of the role MUC4 plays in causing resistance to immunotherapy. The concept of adding a drug to modify the immunosuppressive environment
of the TME to allow immunotherapy to be effective is also new. We will be responsible for educating them on the importance of MUC4 expression,
TAM, MDSC and why INB03 may be an important addition to the oncologist’s armamentarium. We believe educating investors and partners
about new therapeutic opportunities is an easier task than trying to differentiate our company from the many other cancer immunotherapy
companies. We plan to use a combination of publication, presentation and investor relations to discuss INKmune and INB03 and to educate
the clinical, biopharma and investor community on the value of these novel therapeutic approaches.

14

DN-TNF Competition

To our knowledge, there are
no other companies developing a therapy to treat patients with MUC4+HER2+ tumors. This set of biomarkers predicts a tumor that will be
resistant to therapy. We believe MUC4 expression means that patient will be resistant to first line trastuzumab based immunotherapy and
will be resistant to CPI. INB03 is a unique category of cancer therapies. It is does not kill cancer cells. INB03 modulates the immunology
of the TME to make existing therapies more effective. The advantage of this strategy is that it can be used prospectively, and it does
not add toxicity to existing therapy.

INKmune Competition

Our industry is highly competitive
and subject to rapid and significant technological change. Our potential competitors include large pharmaceutical and biotechnology companies,
specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. We believe
that key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability,
reliability, price, and reimbursement level. Many of our potential competitors, including many of the organizations named below, have
substantially greater financial, technical, and human resources than we do and significantly greater experience in the discovery and development
of product candidates, obtaining FDA and other regulatory approvals of products and the commercialization of those products. Accordingly,
our competitors may be more successful than us in obtaining FDA approval for and achieving widespread market acceptance of their drugs.
Our competitors’ drugs may be more effective, or more effectively marketed and sold, than any drug we may commercialize and may
render our product candidates obsolete